| Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. | |
| | |
MedLine Citation:
|
PMID: 12100929 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The percentage of total prostate needle biopsy tissue with cancer was previously found to be a stronger predictor of biochemical failure after radical prostatectomy (RP) than either biopsy Gleason score or serum prostate-specific antigen (PSA). To improve our ability to predict preoperatively the risk of biochemical recurrence after RP, we sought to determine the cutpoints of the percentage of biopsy tissue with cancer to separate patients into low, intermediate, or high-risk groups. We then examined whether we could further stratify low, intermediate, and high-risk groups (on the basis of the PSA level and biopsy Gleason score) using the percentage of prostate needle biopsy tissue with cancer. METHODS: A single pathologist reviewed the prostate needle biopsy specimens of 217 men who underwent RP between 1991 and 2001. Biopsy specimens were examined for Gleason score and the percentage of total biopsy tissue with cancer. Cutpoints were identified to define patients with differing risk of biochemical recurrence after RP. These cutpoints were applied to low, intermediate, and high-risk patients, on the basis of PSA and biopsy Gleason score, to determine whether preoperative risk stratification could be improved. RESULTS: Using the cutpoints for the percentage of prostate needle biopsy tissue with cancer of less than 20% (low risk), 20% to less than 55% (intermediate risk), and 55% or greater (high risk), patients were separated into three groups with differing risks of biochemical failure after RP (hazard ratio 1.95, 95% confidence interval 1.37 to 2.77, P <0.001). These cutpoints further stratified patients with an intermediate (P = 0.002) or high risk (P = 0.05) of biochemical failure (on the basis of the PSA and biopsy Gleason score). However, these cutpoints provided no improvement in risk stratification for patients who were at low risk (P = 0.501) of biochemical failure (on the basis of PSA and biopsy Gleason score). CONCLUSIONS: The percentage of total prostate needle biopsy tissue with cancer can be used to stratify patients into low, intermediate, and high-risk groups preoperatively for biochemical recurrence after RP. These cutpoints could further stratify patients preoperatively who were at intermediate or high risk of biochemical failure on the basis of PSA and biopsy Gleason score. |
| | |
Authors:
|
Stephen J Freedland; George S Csathy; Frederick Dorey; William J Aronson |
Related Documents
:
|
21524569 - Metastatic triple-negative breast cancer. 3739009 - Excision of oral leukoplakias by co2 laser on an out-patient basis: a useful procedure ... 10475359 - Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: pr... 2667689 - Extended role for needle biopsy in the management of carcinoma of the breast. 16130139 - Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. 18499849 - Three-dimensional sonography with needle tracking: role in diagnosis and treatment of p... 12487259 - Sentinel lymph node biopsy in patients with thyroid carcinoma. 17627009 - Early- and late-onset breast cancer types among women in the united states and japan. 19115699 - Ectopic breast cancer in the anterior chest wall: a case report and literature review. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Urology Volume: 60 ISSN: 1527-9995 ISO Abbreviation: Urology Publication Date: 2002 Jul |
Date Detail:
|
Created Date: 2002-07-08 Completed Date: 2002-09-13 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: United States |
Other Details:
|
Languages: eng Pagination: 84-8 Citation Subset: IM |
Affiliation:
|
Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90095-1738, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biopsy, Needle Confidence Intervals Humans Male Middle Aged Neoplasm Recurrence, Local / diagnosis, epidemiology Neoplasm Staging Prognosis Proportional Hazards Models Prostate / pathology* Prostate-Specific Antigen / blood Prostatectomy* Prostatic Neoplasms / blood, pathology*, surgery Risk Factors Survival Analysis |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Epidemiologic association between prostatitis and prostate cancer.
Next Document: Comparison of local anesthesia techniques during transrectal ultrasound-guided biopsies.